AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (2.3 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

TP53BP2: Roles in suppressing tumorigenesis and therapeutic opportunities

Yunfei Huo, Ke Cao, Buxin Kou, Mengyin Chai, Shuangshuang Dou, Dexi Chen, Ying Shi,( ), Xiaoni Liu,( )
Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China

Peer review under responsibility of Chongqing Medical University.

Show Author Information

Abstract

Malignant tumor is still a major problem worldwide. During tumorigenesis or tumor development, tumor suppressor p53-binding protein 2 (TP53BP2), also known as apoptosis stimulating protein 2 of p53 (ASPP2), plays a critical role in p53 dependent and independent manner. Expression of TP53BP2 is highly correlated with the prognosis and survival rate of malignant tumor patients. TP53BP2 can interact with p53, NF-κB p65, Bcl-2, HCV core protein, PP1, YAP, CagA, RAS, PAR3, and other proteins to regulate cell function. Moreover, TP53BP2 can also regulate the proliferation, apoptosis, autophagy, migration, EMT and drug resistance of tumor cells through downstream signaling pathways, such as NF-κB, RAS/MAPK, mevalonate, TGF-β1, PI3K/AKT, aPKC-ι/GLI1 and autophagy pathways. As a potential therapeutic target, TP53BP2 has been attracted more attention. We review the role of TP53BP2 in tumorigenesis or tumor development and the signal pathway involved in TP53BP2, which may provide more deep insight and strategies for tumor treatment.

Keywords

Signaling pathwaysTumorigenesisTP53Binding proteinsTP53BP2Tumor development

References

1

Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J. 2021;134(7):783-791.
Crossref Google Scholar
2

Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070. Nat Rev Clin Oncol. 2021;18(10):663-672.
Crossref Google Scholar
3

Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81(3):323-330.
Crossref Google Scholar
4

Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature. 1992;359(6392):235-237.
Crossref Google Scholar
5

Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000;77:81-137.
Crossref Google Scholar
6

Ryan KM, Vousden KH. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol. 1998;18(7):3692-3698.
Crossref Google Scholar
7

Liu ZJ, Lu X, Zhang Y, et al. Downregulated mRNA expression of ASPP and the hypermethylation of the 5'-untranslated region in cancer cell lines retaining wild-type p53. FEBS Lett. 2005;579(7):1587-1590.
Crossref Google Scholar
8

Iwabuchi K, Bartel PL, Li B, Marraccino R, Fields S. Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci U S A. 1994;91(13):6098-6102.
Crossref Google Scholar
9

Joerger AC, Ang HC, Veprintsev DB, Blair CM, Fersht AR. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J Biol Chem. 2005;280(16):16030-16037.
Crossref Google Scholar
10

Gorina S, Pavletich NP. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science. 1996;274(5289):1001-1005.
Crossref Google Scholar
11

Liang B, Chen R, Song S, et al. ASPP2 inhibits tumor growth by repressing the mevalonate pathway in hepatocellular carcinoma. Cell Death Dis. 2019;10(11):830.
Crossref Google Scholar
12

Li H, Wang X, Zhang C, et al. HDAC1-induced epigenetic silencing of ASPP2 promotes cell motility, tumour growth and drug resistance in renal cell carcinoma. Cancer Lett. 2018;432:121-131.
Crossref Google Scholar
13

Wu T, Song H, Xie D, et al. Silencing of ASPP2 promotes the proliferation, migration and invasion of triple-negative breast cancer cells via the PI3K/AKT pathway. Int J Oncol. 2018;52(6):2001-2010.
Crossref Google Scholar
14

Liu X, Wang S, Guo X, et al. Exogenous p53 and ASPP2 expression enhances rAdV-TK/GCV-induced death in hepatocellular carcinoma cells lacking functional p53. Oncotarget. 2016;7(14):18896-18905.
Crossref Google Scholar
15

Li S, Shi G, Yuan H, et al. Abnormal expression pattern of the ASPP family of proteins in human non-small cell lung cancer and regulatory functions on apoptosis through p53 by iASPP. Oncol Rep. 2012;28(1):133-140.
Crossref Google Scholar
16

Gen Y, Yasui K, Kitaichi T, et al. ASPP2 suppresses invasion and TGF-β1-induced epithelial-mesenchymal transition by inhibiting Smad7 degradation mediated by E3 ubiquitin ligase ITCH in gastric cancer. Cancer Lett. 2017;398:52-61.
Crossref Google Scholar
17

Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307-310.
Crossref Google Scholar
18

Levine AJ. Targeting therapies for the p53 protein in cancer treatments. Annu Rev Cell Biol. 2019;3:21-34.
Crossref Google Scholar
19

Samuels-Lev Y, O'Connor DJ, Bergamaschi D, et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell. 2001;8(4):781-794.
Crossref Google Scholar
20

Naumovski L, Cleary ML. The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. Mol Cell Biol. 1996;16(7):3884-3892.
Crossref Google Scholar
21

Ahn J, Byeon IL, Byeon CH, Gronenborn AM. Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins. J Biol Chem. 2009;284(20):13812-13822.
Crossref Google Scholar
22

Robinson RA, Lu X, Jones EY, Siebold C. Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73. Structure. 2008;16(2):259-268.
Crossref Google Scholar
23

Katz C, Benyamini H, Rotem S, et al. Molecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2. Proc Natl Acad Sci U S A. 2008;105(34):12277-12282.
Crossref Google Scholar
24

Yang JP, Hori M, Takahashi N, Kawabe T, Kato H, Okamoto T. NF-kappaB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2. Oncogene. 1999;18(37):5177-5186.
Crossref Google Scholar
25

Benyamini H, Leonov H, Rotem S, Katz C, Arkin IT, Friedler A. A model for the interaction between NF-kappa-B and ASPP2 suggests an I-kappa-B-like binding mechanism. Proteins. 2009;77(3):602-611.
Crossref Google Scholar
26

Cao Y, Hamada T, Matsui T, Date T, Iwabuchi K. Hepatitis C virus core protein interacts with p53-binding protein, 53BP2/Bbp/ASPP2, and inhibits p53-mediated apoptosis. Biochem Biophys Res Commun. 2004;315(4):788-795.
Crossref Google Scholar
27

Nakagawa H, Koyama K, Murata Y, Morito M, Akiyama T, Nakamura Y. APCL, a central nervous system-specific homologue of adenomatous polyposis coli tumor suppressor, binds to p53-binding protein 2 and translocates it to the perinucleus. Cancer Res. 2000;60(1):101-105.
Google Scholar
28

Hakuno F, Kurihara S, Watson RT, Pessin JE, Takahashi SI. 53BP2S, interacting with insulin receptor substrates, modulates insulin signaling. J Biol Chem. 2007;282(52):37747-37758.
Crossref Google Scholar
29

Liu C, Luan J, Bai Y, et al. Aspp2 negatively regulates body growth but not developmental timing by modulating IRS signaling in zebrafish embryos. Gen Comp Endocrinol. 2014;197:82-91.
Crossref Google Scholar
30

Langton PF, Colombani J, Aerne BL, Tapon N. Drosophila ASPP regulates C-terminal Src kinase activity. Dev Cell. 2007;13(6):773-782.
Crossref Google Scholar
31

Helps NR, Barker HM, Elledge SJ, Cohen PT. Protein phosphatase 1 interacts with p53BP2, a protein which binds to the tumour suppressor p53. FEBS Lett. 1995;377(3):295-300.
Crossref Google Scholar
32

Bertran MT, Mouilleron S, Zhou Y, et al. ASPP proteins discriminate between PP1 catalytic subunits through their SH3 domain and the PP1 C-tail. Nat Commun. 2019;10(1):771.
Crossref Google Scholar
33

Royer C, Sandham E, Slee E, et al. ASPP2 maintains the integrity of mechanically stressed pseudostratified epithelia during morphogenesis. Nat Commun. 2022;13(1):941.
Crossref Google Scholar
34

Espanel X, Sudol M. Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. J Biol Chem. 2001;276(17):14514-14523.
Crossref Google Scholar
35

Romero-Perez L, Garcia-Sanz P, Mota A, et al. A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer. Mod Pathol. 2015;28(11):1492-1503.
Crossref Google Scholar
36

Konno T, Kohno T, Okada T, et al. ASPP2 suppression promotes malignancy via LSR and YAP in human endometrial cancer. Histochem Cell Biol. 2020;154(2):197-213.
Crossref Google Scholar
37

Janke K, Brockmeier U, Kuhlmann K, et al. Factor inhibiting HIF-1 (FIH-1) modulates protein interactions of apoptosis-stimulating p53 binding protein 2 (ASPP2). J Cell Sci. 2013;126(Pt 12):2629-2640.
Crossref Google Scholar
38

Buti L, Ruiz-Puig C, Sangberg D, et al. CagA-ASPP2 complex mediates loss of cell polarity and favors H. pylori colonization of human gastric organoids. Proc Natl Acad Sci U S A. 2020;117(5):2645-2655.
Crossref Google Scholar
39

Nesic D, Buti L, Lu X, Stebbins CE. Structure of the Helicobacter pylori CagA oncoprotein bound to the human tumor suppressor ASPP2. Proc Natl Acad Sci U S A. 2014;111(4):1562-1567.
Crossref Google Scholar
40

Buti L, Spooner E, Van der Veen AG, Rappuoli R, Covacci A, Ploegh HL. Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Proc Natl Acad Sci U S A. 2011;108(22):9238-9243.
Crossref Google Scholar
41

Wang Y, Godin-Heymann N, Wang XD, Bergamaschi D, Llanos S, Lu X. ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells. Cell Death Differ. 2013;20(4):525-534.
Crossref Google Scholar
42

Sottocornola R, Royer C, Vives V, et al. ASPP2 binds Par-3 and controls the polarity and proliferation of neural progenitors during CNS development. Dev Cell. 2010;19(1):126-137.
Crossref Google Scholar
43

Chen Y, Liu W, Naumovski L, Neve RL. ASPP2 inhibits APP-BP1-mediated NEDD8 conjugation to cullin-1 and decreases APP-BP1-induced cell proliferation and neuronal apoptosis. J Neurochem. 2003;85(3):801-809.
Crossref Google Scholar
44

Sun WT, Hsieh PC, Chiang ML, Wang MC, Wang FF. p53 target DDA3 binds ASPP2 and inhibits its stimulation on p53-mediated BAX activation. Biochem Biophys Res Commun. 2008;376(2):395-398.
Crossref Google Scholar
45

Uhlmann-Schiffler H, Kiermayer S, Stahl H. The DEAD box protein Ddx42p modulates the function of ASPP2, a stimulator of apoptosis. Oncogene. 2009;28(20):2065-2073.
Crossref Google Scholar
46

Rotem S, Katz C, Benyamini H, et al. The structure and interactions of the proline-rich domain of ASPP2. J Biol Chem. 2008;283(27):18990-18999.
Crossref Google Scholar
47

Chen R, Wang H, Liang B, et al. Downregulation of ASPP2 improves hepatocellular carcinoma cells survival via promoting BECN1-dependent autophagy initiation. Cell Death Dis. 2016;7(12):e2512.
Crossref Google Scholar
48

Xu P, Shi H, Jiao Y, Chen D, Shi H. [TP53BP2/ASPP2 inhibits autophagy of HepG2 cells by activating mTOR pathway in a p53-independent manner]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2019;35(11):986-991.
Google Scholar
49

Liu K, Jiang T, Ouyang Y, et al. Nuclear EGFR impairs ASPP2-p53 complex-induced apoptosis by inducing SOS1 expression in hepatocellular carcinoma. Oncotarget. 2015;6(18):16507-16516.
Crossref Google Scholar
50

Liu K, Lin D, Ouyang Y, et al. Amphiregulin impairs apoptosis-stimulating protein 2 of p53 overexpression-induced apoptosis in hepatoma cells. Tumour Biol. 2017;39(3):1010428317695026.
Crossref Google Scholar
51

Wang S, Kou B, Chai M, et al. Knockout of ASPP2 promotes DEN-induced hepatocarcinogenesis via the NF-κB pathway in mice. Cancer Gene Ther. 2022;29(2):202-214.
Crossref Google Scholar
52

Yang T, Gao Y, Liu D, et al. ASPP2 enhances chemotherapeutic sensitivity through the down-regulation of XIAP expression in a p53 independent manner in hepatocellular carcinoma. Biochem Biophys Res Commun. 2019;508(3):769-774.
Crossref Google Scholar
53

Xu L, Tong X, Zhang S, et al. ASPP2 suppresses stem cell-like characteristics and chemoresistance by inhibiting the Src/FAK/Snail axis in hepatocellular carcinoma. Tumour Biol. 2016;37(10):13669-13677.
Crossref Google Scholar
54

Mao J, Tan Z, Pan X, Meng F. ASPP2 expression predicts the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. Exp Ther Med. 2021;21(4):397.
Crossref Google Scholar
55

Wu T, Song H, Xie D, et al. miR-30b-5p promotes proliferation, migration, and invasion of breast cancer cells via targeting ASPP2. BioMed Res Int. 2020;2020:7907269.
Crossref Google Scholar
56

Schipper K, Drenth AP, van der Burg E, et al. Truncated ASPP2 drives initiation and progression of invasive lobular carcinoma via distinct mechanisms. Cancer Res. 2020;80(7):1486-1497.
Crossref Google Scholar
57

Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784-789.
Crossref Google Scholar
58

Ruggiero P. Helicobacter pylori infection: what's new. Curr Opin Infect Dis. 2012;25(3):337-344.
Crossref Google Scholar
59

Meng WD, Chu RX, Wang BZ, Wang LP, Ma LL, Wang LX. Helicobacter pylori infection and expressions of apoptosis-related proteins p53, ASPP2 and iASPP in gastric cancer and precancerous lesions. Pathol Biol. 2013;61(5):199-202.
Crossref Google Scholar
60

Liu WK, Jiang XY, Ren JK, Zhang ZX. Expression pattern of the ASPP family members in endometrial endometrioid adenocarcinoma. Onkologie. 2010;33(10):500-503.
Crossref Google Scholar
61

Patel KD, Barasiya YV, Patel JB, Patel PS. Apoptosis stimulating protein of p53 (ASPP) 1 and ASPP2 m-RNA expression in oral cancer. Arch Oral Biol. 2020;119:104920.
Crossref Google Scholar
62

Huang W, Li X, Cai L. Effects of ASPP2 on proliferation and apoptosis of malignant spinal tumor cells. Int J Clin Exp Pathol. 2017;10(7):8023-8030.
Google Scholar
63

Liu B, Yang L, Li XJ, et al. Expression and significance of ASPP2 in squamous carcinoma of esophagus. Kaohsiung J Med Sci. 2018;34(6):321-329.
Crossref Google Scholar
64

Yin L, Lin Y, Wang X, et al. The family of apoptosis-stimulating proteins of p53 is dysregulated in colorectal cancer patients. Oncol Lett. 2018;15(5):6409-6417.
Crossref Google Scholar
65

Tian L, Deng Z, Xu L, et al. Downregulation of ASPP2 promotes gallbladder cancer metastasis and macrophage recruitment via aPKC-ι/GLI1 pathway. Cell Death Dis. 2018;9(11):1115.
Crossref Google Scholar
66

Song B, Bian Q, Zhang YJ, et al. Downregulation of ASPP2 in pancreatic cancer cells contributes to increased resistance to gemcitabine through autophagy activation. Mol Cancer. 2015;14:177.
Crossref Google Scholar
67

Van Hook K, Wang Z, Chen D, et al. ΔN-ASPP2, a novel isoform of the ASPP2 tumor suppressor, promotes cellular survival. Biochem Biophys Res Commun. 2017;482(4):1271-1277.
Crossref Google Scholar
68

Rieger I, Tsintari V, Overkamp M, et al. ASPP2κ is expressed in human colorectal carcinoma and promotes chemotherapy resistance and tumorigenesis. Front Mol Biosci. 2021;8:727203.
Crossref Google Scholar
69

Liang DY, Sha S, Yi Q, et al. Hepatitis B X protein upregulates decoy receptor 3 expression via the PI3K/NF-κB pathway. Cell Signal. 2019;62:109346.
Crossref Google Scholar
70

DiDonato JA, Mercurio F, Karin M. NF-κB and the link between inflammation and cancer. Immunol Rev. 2012;246(1):379-400.
Crossref Google Scholar
71

He G, Karin M. NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res. 2011;21(1):159-168.
Crossref Google Scholar
72

Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene. 2001;20(31):4188-4197.
Crossref Google Scholar
73

Tordella L, Koch S, Salter V, et al. ASPP2 suppresses squamous cell carcinoma via RelA/p65-mediated repression of p63. Proc Natl Acad Sci U S A. 2013;110(44):17969-17974.
Crossref Google Scholar
74

Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11-22.
Crossref Google Scholar
75

Wang Z, Liu Y, Takahashi M, et al. N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence. Proc Natl Acad Sci U S A. 2013;110(1):312-317.
Crossref Google Scholar
76

Godin-Heymann N, Wang Y, Slee E, Lu X. Phosphorylation of ASPP2 by RAS/MAPK pathway is critical for its full pro-apoptotic function. PLoS One. 2013;8(12):e82022.
Crossref Google Scholar
77

Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5(1):e189.
Crossref Google Scholar
78

Moon SH, Huang CH, Houlihan SL, et al. p53 represses the mevalonate pathway to mediate tumor suppression. Cell. 2019;176(3):564-580.
Crossref Google Scholar
79

Dooley KA, Millinder S, Osborne TF. Sterol regulation of 3-hydroxy-3-methylglutaryl-coenzyme A synthase gene through a direct interaction between sterol regulatory element binding protein and the trimeric CCAAT-binding factor/nuclear factor Y. J Biol Chem. 1998;273(3):1349-1356.
Crossref Google Scholar
80

Lin M, Chang Y, Xie F, Shi Y, Pang L, Chen D. ASPP2 inhibits the profibrotic effects of transforming growth factor-β1 in hepatic stellate cells by reducing autophagy. Dig Dis Sci. 2018;63(1):146-154.
Crossref Google Scholar
81

Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009;19(2):156-172.
Crossref Google Scholar
82

Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170(4):605-635.
Crossref Google Scholar
83

Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13(22):2905-2927.
Crossref Google Scholar
84

Zhou L, Li S, Sun J. Ginkgolic acid induces apoptosis and autophagy of endometrial carcinoma cells via inhibiting PI3K/Akt/mTOR pathway in vivo and in vitro. Hum Exp Toxicol. 2021;40(12):2156-2164.
Crossref Google Scholar
85

Yu T, An Q, Cao XL, et al. GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway. Life Sci. 2020;260:118294.
Crossref Google Scholar
86

Blotta S, Jakubikova J, Calimeri T, et al. Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood. 2012;120(25):5002-5013.
Crossref Google Scholar
87

Justilien V, Walsh MP, Ali SA, Thompson EA, Murray NR, Fields AP. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell. 2014;25(2):139-151.
Crossref Google Scholar
88

Gual P, Gilgenkrantz H, Lotersztajn S. Autophagy in chronic liver diseases: the two faces of Janus. Am J Physiol Cell Physiol. 2017;312(3):C263-C273.
Crossref Google Scholar
89

Wang Y, Wang XD, Lapi E, et al. Autophagic activity dictates the cellular response to oncogenic RAS. Proc Natl Acad Sci U S A. 2012;109(33):13325-13330.
Crossref Google Scholar
90

Liu X, Xu J, Wang S, et al. Synergistic inhibitory effects on hepatocellular carcinoma with recombinant human adenovirus Aspp2 and oxaliplatin via p53-independent pathway in vitro and in vivo. Int J Oncol. 2017;51(4):1291-1299.
Crossref Google Scholar
91

Hou Q, Zhao H, Gong W, et al. [Phosphorylation status of ASPP2 modulates p53 apoptotic function in oxaliplatin-induced apoptosis of colorectal cancer HCT116 cells]. Zhonghua Zhongliu Zazhi. 2014;36(6):418-423.
Google Scholar
92

Shi Y, Han Y, Xie F, et al. ASPP2 enhances oxaliplatin (L-OHP)-induced colorectal cancer cell apoptosis in a p53-independent manner by inhibiting cell autophagy. J Cell Mol Med. 2015;19(3):535-543.
Crossref Google Scholar
93

Wang YP, Zhou L, Gong XG. [Pro-apoptotic effects of luteolin on hepatoma HepG2 cells]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2013;42(5):504-510.
Google Scholar
94

Chen D, Padiernos E, Ding F, Lossos IS, Lopez CD. Apoptosis-stimulating protein of p53-2 (ASPP2/53BP2L) is an E2F target gene. Cell Death Differ. 2005;12(4):358-368.
Crossref Google Scholar
95

Turnquist C, Wang Y, Severson DT, et al. STAT1-induced ASPP2 transcription identifies a link between neuroinflammation, cell polarity, and tumor suppression. Proc Natl Acad Sci U S A. 2014;111(27):9834-9839.
Crossref Google Scholar
96

Richter AM, Küster MM, Woods ML, et al. RASSF10 is a TGFβ-target that regulates ASPP2 and E-cadherin expression and acts as tumor suppressor that is epigenetically downregulated in advanced cancer. Cancers. 2019;11(12):1976.
Crossref Google Scholar
97

Liu L, Wang L, Li X, et al. Effect of miR-21 on apoptosis in hepatoblastoma cell through activating ASPP2/p38 signaling pathway in vitro and in vivo. Artif Cell Nanomed Biotechnol. 2019;47(1):3729-3736.
Crossref Google Scholar
Genes & Diseases
Volume 10 Issue 5,
September 2023
Pages 1982-1993
DOI: 10.1016/j.gendis.2022.08.014
Cite this article:
Huo Y, Cao K, Kou B, et al. TP53BP2: Roles in suppressing tumorigenesis and therapeutic opportunities. Genes & Diseases, 2023, 10(5): 1982-1993. https://doi.org/10.1016/j.gendis.2022.08.014

247

Views

4

Downloads

7

Crossref

5

Web of Science

5

Scopus

0

CSCD

Altmetrics
Received: 11 May 2022
Accepted: 12 August 2022
Published: 05 September 2022
© 2022 The Authors.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return